Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate and toxicity
6 months
Yes
Jacob Schachter, MD
Principal Investigator
Head, Ella Institute, Sheba Medical Center
Israel: Israeli Health Ministry Pharmaceutical Administration
SHEBA-04-3518-JS-CTIL
NCT00287131
January 2006
November 2013
Name | Location |
---|